Bristol-Myers Squibb Company (BMS) and the ADAP Crisis Task Force (ACTF) have agreed to enhanced support by BMS of AIDS Drug Assistance Programs (ADAPs), according to a BMS statement. This new multi-year agreement builds on a previous agreement in March to provide continued access to BMS drugs Reyataz (atazanavir) and Sustiva (efavirenz). BMS also continues to offer help through its “Access Virology” program, which evaluates eligibility for other prescription assistance programs.

To read the BMS statement, click here.